Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CarMax, Inc (KMX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

CarMax, IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

CarMax, Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? CarMax, Inc trades at $58.03 (market cap $8.26B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.3× CarMax, Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.

KMXVRTX
Market Cap
$8.26B$134.25B
Sector
Consumer CyclicalHealth
52-Week High
$62.17$529.65
52-Week Low
$30.88$376.62
Enterprise Value
$26.77B$128.37B

Returns comparison

Trailing returns across standard periods

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX